		Technical Data
B0807-07A	Bcl 2a (B Cell Leukemia 2a)

Description:
Expression of bcl-2a oncoprotein has been shown to inhibit the programmed cell death (apoptosis). In most follicular lymphomas, neoplastic germinal centers express high levels of bcl-2a protein, whereas the normal or hyperplastic germinal centers are negative.

Bcl-2 belongs to a family of genetically related proteins that appear to regulate apoptosis or programmed cell death. Bcl-2 is encoded by a proto-oncogene (bcl-2) that is the mammalian homolog of ced-9, the C. elegans death suppressor gene. Overexpression of Bcl-2 appears to suppress apoptosis in a number of mammalian experimental systems. Recent evidence indicates that Bcl-2 binds to other family members and R-ras and influences antioxidant pathways in the cell. Bcl-2 is a 25kDa protein that has extensive amino acid homology with Bax. It forms homodimers or heterodimers with Bax and the apoptotic activity depends on the balance of both molecules. The t(14;18) translocation, which is a hallmark of human follicular lymphoma, generally involves the immunoglobulin heavy chain gene on chromosome 14 and the bcl-2 gene on chromosome 18. This translocation results in overexpression of the bcl-2 gene product (Bcl-2), promoting cell survival by blocking programmed cell death induced by different apoptotic stimuli.

Expression of Bcl 2a oncoprotein has been shown to inhibit the programmed cell death (apoptosis). In most follicular lymphomas, neoplastic germinal centers express high levels of bcl-2a protein, whereas the normal or hyperplastic germinal centers are negative.

Applications:
Suitable for use in Immunofluorescence, Flow Cytometry, ELISA, Western Blot, Immunoprecipitation, and Immunohistochemistryy. Other applications not tested.

Recommended Dilution:
Western Blot: 1-2ug/ml for two hours at RT.
Immunohistochemistry (Formalin/paraffin): 2-4ug/ml for 30 minutes at RT with high-sensitivity detection system. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0 for 10-20 min, followed by cooling at RT for 20 min.
Immunoprecipitation: 2ug antibody/mg protein lysate using Protein G.
Optimal dilutions to be determined by the researcher.

Positive Control:
Raji Cells. Tonsil and follicular lymphomas.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile 40-50% glycerol, aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Type	Isotype	Clone	Grade
Mab	IgG1,k	0.N.23	Affinity Purified

Size		Storage	Shipping	Source	Host
500ul		4°C (-20°C Glycerol)	Blue Ice	Human	Mouse

Concentration:

0.2mg/ml

Immunogen:

Synthetic peptide corresponding to residues 41-54 (GAAPAPGIFSSQPG-Cys) of human Bcl-2 protein. Cellular Localization: cytoplasm, cell membrance

Purity:

Purified by Protein G affinity chromatography.

Form

Supplied as a liquid in PBS, pH 7.4, 0.2% BSA, 0.09% sodium azide. Also available without BSA and azide. See B0807-07AX.

Specificity:

Recognizes human Bcl-2a at ~25kDa. Does not react with mouse or rat.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

1. Pezzella F et. al.. American Journal of Pathology, 1990, 137(2):225-32.1. Alderson LM; Castleberg RL; Harsh GR 4th; Louis DN; Henson JW. Human gliomas with wild-type p53 express bcl-2. Cancer Research, 1995 Mar 1, 55(5):999-1001.2. Ashton-Key M; Biddolph SC; Stein H; Gatter KC; Mason DY. Heterogeneity of bcl-2 expression in MALT lymphoma. Histopathology, 1995 Jan, 26(1):75-8.
3. Bargou RC; Daniel PT; Mapara MY; Bommert K; Wagener C; Kallinich B; Royer HD; Dorken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. International Journal of Cancer, 1995 Mar 16, 60(6):854-9.
4. Bensi L; Longo R; Vecchi A; Messora C; Garagnani L; Bernardi S; Tamassia MG; Sacchi S. Bcl-2 oncoprotein expression in acute myeloid leukemia. Haematologica, 1995, 80(2):98-102.
5. Bosari S; Moneghini L; Graziani D; Lee AK; Murray JJ; Coggi G; Viale G. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Human Pathology, 1995 May, 26(5):534-40.
6. Ceccarelli C; Santini D; Chieco P; Taffurelli M; Marrano D; Mancini AM. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour. Annals of Oncology, 1995 Mar, 6(3):275-82.
7. Cerroni L; Soyer HP; Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. American Journal of Dermatopathology, 1995 Feb, 17(1):7-11.
8. Chetty R; O’Leary JJ; Biddolph SC; Gatter KC. Immunohistochemical detection of p53 and Bcl-2 proteins in Hashimoto’s thyroiditis and primary thyroid lymphomas. Journal of Clinical Pathology, 1995 Mar, 48(3):239-41.
9. Dummer R; Michie SA; Kell D; Gould JW; Haeffner AC; Smoller BR; Warnke RA; Wood GS. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. Journal of Cutaneous Pathology, 1995 Feb, 22(1):11-7.
10. Fontanini G; Vignati S; Bigini D; Mussi A; Lucchi M; Angeletti CA; Basolo F; Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. British Journal of Cancer, 1995 May, 71(5):1003-7.
11. Gorczyca W; Markiewski M; Kram A; Tuziak T; Domagala W. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Archiv, 1995, 426(3):229-33.
12. Higashiyama M; Doi O; Kodama K; Yokouchi H; Tateishi R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Research, 1995 Mar-Apr, 15(2):503-5.
13. Hoehner JC; Hedborg F; Wiklund HJ; Olsen L; Pahlman S. Cellular death in neuroblastoma: in situ correlation of apoptosis and bcl-2 expression. International Journal of Cancer, 1995, 62(1):19-24.
14. Hurlimann J; Larrinaga B; Vala DL. bcl-2 protein in invasive ductal breast carcinomas. Virchows Archiv, 1995, 426(2):163-8.
15. Ikegaki N; Katsumata M; Tsujimoto Y; Nakagawara A; Brodeur GM. Relationship between bcl-2 and myc gene expression in human neuroblastoma. Cancer Letters, 1995 May 8, 91(2):161-8.
16. Jaattela M; Benedict M; Tewari M; Shayman JA; Dixit VM. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene, 1995 Jun 15, 10(12):2297-305.
17. Jacobson MD; Raff MC. Programmed cell death and Bcl-2 protection in very low oxygen. Nature, 1995 Apr 27, 374(6525):814-6.
18. Kinoshita T; Yokota T; Arai K; Miyajima A. Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene, 1995 Jun 1, 10(11):2207-12.
19. Krajewski S; Bodrug S; Krajewska M; Shabaik A; Gascoyne R; Berean K; Reed JC. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. American Journal of Pathology, 1995 Jun, 146(6):1309-19.
20. Krajewski S; Chatten J; Hanada M; Reed JC. Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein. Laboratory Investigation, 1995 Jan, 72(1):42-54.
21. Lauwers GY; Scott GV; Karpeh MS. Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer, 1995 May 1, 75(9):2209-13.
22. Le PT; Maecker HT; Cook JE. In situ detection and characterization of apoptotic thymocytes in human thymus. Expression of bcl-2 in vivo does not prevent apoptosis. Journal of Immunology, 1995 May 1, 154(9):4371-8.
23. Leoncini L; Del Vecchio MT; Spina D; Megha T; Barbini P; Sabattini E; Pileri S; Tosi P; Kraft R; Laissue JA; et al. Presence of the bcl-2 protein and apoptosis in non-Hodgkin lymphomas with diffuse growth pattern. International Journal of Cancer, 1995 Jun 9, 61(6):826-31.
24. Lepelley P; Soenen V; Preudhomme C; Merlat A; Cosson A; Fenaux P. bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia, 1995 Apr, 9(4):726-30.
25. Lipponen P; Eskelinen M; Syrjanen K. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. British Journal of Cancer, 1995 Apr, 71(4):863-7.
26. Lu PJ; Lu QL; Rughetti A; Taylor-Papadimitriou J. bcl-2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorigenesis of human mammary epithelial cells. Journal of Cell Biology, 1995 Jun, 129(5):1363-78.
27. Massaia M; Borrione P; Attisano C; Barral P; Beggiato E; Montacchini L; Bianchi A; Boccadoro M; Pileri A. Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood, 1995, 85(12):3679-87.
28. Navratil E; Gaulard P; Kanavaros P; Audouin J; Bougaran J; Martin N; Diebold J; Mason DY. Expression of the bcl-2 protein in B cell lymphomas arising from mucosa associated lymphoid tissue. Journal of Clinical Pathology, 1995 Jan, 48(1):18-21.
29. Ong F; van Nieuwkoop JA; de Groot-Swings GM; Hermans J; Harvey MS; Kluin PM; Kluin-Nelemans JC. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia, 1995 Jul, 9(7):1282-4.
30. Park JR; Bernstein ID; Hockenbery DM. Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood, 1995, 86(3):868-76.
31. Plettenberg A; Ballaun C; Pammer J; Mildner M; Strunk D; Weninger W; Tschachler E. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. American Journal of Pathology, 1995 Mar, 146(3):651-9.
32. Porwit-MacDonald A; Ivory K; Wilkinson S; Wheatley K; Wong L; Janossy G. Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia. Leukemia, 1995 Jul, 9(7):1191-8.
33. Ramsay JA; From L; Kahn HJ. bcl-2 protein expression in melanocytic neoplasms of the skin. Modern Pathology, 1995 Feb, 8(2):150-4.
34. Shimizu S; Eguchi Y; Kosaka H; Kamiike W; Matsuda H; Tsujimoto Y. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature, 1995 Apr 27, 374(6525):811-3.
35. Sierra A; Lloveras B; Castellsague X; Moreno L; Garcia-Ramirez M; Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. International Journal of Cancer, 1995 Jan 3, 60(1):54-60.
36. Sinicrope FA; Ruan SB; Cleary KR; Stephens LC; Lee JJ; Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Research, 1995 Jan 15, 55(2):237-41.
37. Symmans WF; Katz RL; Ordonez NG; Dalton H; Romaguera JE; Cabanillas F. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytologica, 1995 Jul-Aug, 39(4):673-82.
38. Triscott JA; Ritter JH; Swanson PE; Wick MR. Immunoreactivity for bcl-2 protein in cutaneous lymphomas and lymphoid hyperplasias. Journal of Cutaneous Pathology, 1995 Feb, 22(1):2-10.
39. Tron VA; Krajewski S; Klein-Parker H; Li G; Ho VC; Reed JC. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. American Journal of Pathology, 1995 Mar, 146(3):643-50.
40. Umemura S; Kawai K; Osamura RY; Tsutsumi Y. Antigen retrieval for bcl-2 protein in formalin-fixed, paraffin-embedded sections. Pathology International, 1995 Feb, 45(2):103-7.
41. Verhaegh ME; Sanders CJ; Arends JW; Neumann HA. Expression of the apoptosis-suppressing protein Bcl-2 in non-melanoma skin cancer. Brit Journal of Dermatol, 1995, 132:740-4.
42. Walker C; Robertson L; Myskow M; Dixon G. Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas. Brit Journal of Cancer, 1995, 72:164-9.
43. Weinreb M; Day PJ; Niggli F; Raafat F; Mann JR. BCL-2 oncoprotein in neuroblastoma [letter]. Lancet, 1995 Apr 15, 345(8955):992-3.
44. Akagi T; Kondo E; Yoshino T. Expression of Bcl-2 protein and Bcl-2 mRNA in normal and neoplastic lymphoid tissues. Leukemia and Lymphoma, 1994 Mar, 13(1-2):81-7.
45. Ben-Ezra JM; King BE; Harris AC; Todd WM; Kornstein MJ. Staining for Bcl-2 protein helps to distinguish benign from malignant lymphoid aggregates in bone marrow biopsies. Modern Pathology, 1994 Jun, 7(5):560-4.
46. Ben-Ezra JM; Kornstein MJ; Grimes MM; Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. American Journal of Pathology, 1994 Nov, 145(5):1036-40.
47. Bhargava V; Kell DL; van de Rijn M; Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. American Journal of Pathology, 1994 Sep, 145(3):535-40.
48. Cerroni L; Kerl H. Aberrant bcl-2 protein expression provides a possible mechanism of neoplastic cell growth in cutaneous basal-cell carcinoma. J of Cutaneous Patho, 1994, 21:398-403.
49. Cerroni L; Volkenandt M; Rieger E; Soyer HP; Kerl H. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J of Investigative Dermatology, 1994, 102:231-5.
50. Charlotte F; L’Hermine A; Martin N; Geleyn Y; Nollet M; Gaulard P; Zafrani ES. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. American Journal of Pathology, 1994 Mar, 144(3):460-5.
51. de Jong D; Prins FA; Mason DY; Reed JC; van Ommen GB; Kluin PM. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Research, 1994 Jan 1, 54(1):256-60.
52. Doglioni C; Dei Tos AP; Laurino L; Chiarelli C; Barbareschi M; Viale G. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Archiv, 1994, 424(1):47-51.
53. Dole M; Nunez G; Merchant AK; Maybaum J; Rode CK; Bloch CA; Castle VP. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Research, 1994 Jun 15, 54(12):3253-9.
54. Gaffney EF; O’Neil AJ; Staunton MJ. bcl-2 and prognosis in non-small-cell lung carcinoma [letter; comment]. New Eng J of Med, 1994, 330:1757-8.
55. Gala JL; Vermylen C; Cornu G; Ferrant A; Michaux JL; Philippe M; Martiat P. High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis. Annals of Hematology, 1994 Jul, 69(1):17-24.
56. Gee JM; Robertson JF; Ellis IO; Willsher P; McClelland RA; Hoyle HB; Kyme SR; Finlay P; Blamey RW; Nicholson RI. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. International Journal of Cancer, 1994, 59(5):619-28.
57. Gompel A; Sabourin JC; Martin A; Yaneva H; Audouin J; Decroix Y; Poitout P. Bcl-2 expression in normal endometrium during the menstrual cycle. Am J of Pathology, 1994 Jun, 144(6):1195-202.
58. Hague A; Moorghen M; Hicks D; Chapman M; Paraskeva C. BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene, 1994 Nov, 9(11):3367-70.
59. Ikegaki N; Katsumata M; Minna J; Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Research, 1994 Jan 1, 54(1):6-8.
60. Joensuu H; Pylkkanen L; Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J of Pathology, 1994, 145(5):1191-8.
61. Johnston SR; MacLennan KA; Sacks NP; Salter J; Smith IE; Dowsett M. Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. European Journal of Cancer, 1994, 30A(11):1663-9.
62. Klein-Parker HA; Warshawski L; Tron VA. Melanocytes in human skin express bcl-2 protein. Journal of Cutaneous Pathol, 1994, 21(4):297-301.
63. Kondo E; Yoshino T; Yamadori I; Matsuo Y; Kawasaki N; Minowada J; Akagi T. Expression of Bcl-2 protein and Fas antigen in non-Hodgkin’s lymphomas. Am J of Pathology, 1994, 145(2):330-7.
64. Krajewski S; Bodrug S; Gascoyne R; Berean K; Krajewska M; Reed JC. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J of Pathol, 1994, 145:515-25.
65. Lauwers GY; Scott GV; Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer, 1994 Jun 15, 73(12):2900-4.
66. Leek RD; Kaklamanis L; Pezzella F; Gatter KC; Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. British Journal of Cancer, 1994 Jan, 69(1):135-9.
67. Lones MA; Pinkus GS; Shintaku IP; Said JW. Bcl-2 oncogene protein is preferentially expressed in Reed-Sternberg cells in Hodgkin’s disease of the nodular sclerosis subtype. American Journal of Clinical Pathology, 1994 Oct, 102(4):464-7.
68. Marin MC; Hsu B; Meyn RE; Donehower LA; el-Naggar AK; McDonnell TJ. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene, 1994 Nov, 9(11):3107-12.